Acotec Scientific's Micro-Guidewire Receives Beijing Medical Products Administration Approval
CompanyMedical Device

Acotec Scientific’s Micro-Guidewire Receives Beijing Medical Products Administration Approval

Skyhawk Therapeutics Collaborates with Merck on RNA-Targeting Small Molecules for Neurological Diseases
CompanyDeals

Skyhawk Therapeutics Collaborates with Merck on RNA-Targeting Small Molecules for Neurological Diseases

Sichuan Biokin's Iza-Bren Granted FDA Breakthrough Therapy Designation for NSCLC
CompanyDrug

Sichuan Biokin’s Iza-Bren Granted FDA Breakthrough Therapy Designation for NSCLC

Ascentage Pharma's Lisaftoclax Gains FDA and EMA Clearance for Global Phase III Trial
CompanyDrug

Ascentage Pharma’s Lisaftoclax Gains FDA and EMA Clearance for Global Phase III Trial

Novo Nordisk's Wegovy Granted FDA Approval for Metabolic-Associated Steatohepatitis
CompanyDrug

Novo Nordisk’s Wegovy Granted FDA Approval for Metabolic-Associated Steatohepatitis

Livzon Announces NMPA Acceptance of JP-1366 Tablets Application for Reflux Esophagitis
CompanyDrug

Livzon Announces NMPA Acceptance of JP-1366 Tablets Application for Reflux Esophagitis

iRegene Therapeutics' NouvNeu001 Receives FDA Fast Track Designation for Parkinson's Therapy
CompanyDrug

iRegene Therapeutics’ NouvNeu001 Receives FDA Fast Track Designation for Parkinson’s Therapy

Ab&B Bio-Tech's RSV Vaccine Gains IND Approval in China and the U.S.
CompanyDrug

Ab&B Bio-Tech’s RSV Vaccine Gains IND Approval in China and the U.S.

Haisco's HSK39297 Gains NMPA Approval for AMD and gMG Trials
CompanyDrug

Haisco’s HSK39297 Gains NMPA Approval for AMD and gMG Trials

FDA Accelerates Approval of Dordaviprone for H3 K27M-Mutant Diffuse Midline Glioma
CompanyDrug

FDA Accelerates Approval of Dordaviprone for H3 K27M-Mutant Diffuse Midline Glioma

Ajinomoto and Amphastar Ink Licensing Pact for Oncology and wAMD Drug Candidates
CompanyDeals

Ajinomoto and Amphastar Ink Licensing Pact for Oncology and wAMD Drug Candidates

Hengrui Pharmaceuticals Gains NMPA Approval for SHR-7782 Clinical Trials in Advanced Solid Tumors
CompanyDrug

Hengrui Pharmaceuticals Gains NMPA Approval for SHR-7782 Clinical Trials in Advanced Solid Tumors